The American Bristol-Myers Squibb (BMS) has launched the process of transferring the Russian business to its partner in Central and Eastern Europe - Swixx BioPharma. By the end of June 2022, BMS will close all research sponsored by it in Russia, the publication reportsVademecum.

Employees of the Russian division of BMS were offered to go to work at Swixx BioPharma and promised compensation.

According to the publication, BMS is the first global pharmaceutical company to announce the transfer of commercial operations in the Russian market.

Bristol-Myers Squibb specializes in the development of drugs for the treatment of oncological, endocrine and infectious diseases. BMS produces drugs for the treatment of rheumatoid arthritis "Orensia", antitumor drugs "Opdivo", "Yervoy", "Amplicity", a drug against hepatitis B virus "Baraclud".

In Russia, Swixx is managed by Swix Biopharma and Swix Healthcare, whose combined revenue in 2021 amounted to 3.3 billion rubles.

According to the Register of Clinical Trials, BMS is currently conducting a study of a drug for Crohn's disease, which should be completed in 2024. In 2020-2021, the research of drugs for plaque psoriasis and systemic lupus erythematosus was completed.

Read the operational news in ourTelegram channel

Author: Ulyana Lutskevich
Made in Russia // Made in Russia

#made by Russia